Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...
The FDA approved a new injected version of the cancer immunotherapy drug Keytruda. With injections, patients need only an hour total for treatment, while Keytruda infusion may require two hours.
What Is It, and Why Does It Matter? The FDA has approved a new combination therapy for adults with epithelial cancers that start in the ovaries, fallopian tubes, or lining of the abdomen (peritoneum).
Merck's combination of Keytruda and Lenvima added disease-progression benefit on top of standard transarterial chemoembolization in intermediate-stage liver cancer. (eranicle/iStock/Getty Images Plus) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results